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Dr. Matthew Banks, an assistant professor of 
pharmacology, received the award at VCU’s fall 
convocation. He conducts research on how to 
treat drug addiction.
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The United States is facing a heroin and opioid epidemic, with fatal drug overdoses steadily 
rising over the past 15 years. Scientists and 
doctors are working hard researching addiction 
and developing new ways to treat the growing 
issue.
One such researcher is Dr. Matthew L. Banks, 
an assistant professor in VCU’s Department 
of Pharmacology and Toxicology. For his 
work in this area, Banks recently received the 
university’s Outstanding Early Career Faculty 
Award.
His research centers on two themes – 
developing behavioral and pharmacological 
strategies to treat drug addiction, and making 
existing medications more effective with fewer 
side effects. Much of his work at the Medical 
College of Virginia involves rhesus monkeys.
“The research we do is intended to improve 
human health and also has applications to 
improving veterinary medicine,” said Banks, who 
was honored at VCU’s faculty convocation at the 
start of the fall semester.
Banks received his doctorate in pharmacy from 
Ohio Northern University and his Ph.D. from 
Wake Forest University. He was introduced 
to drug abuse research in pharmacy school, 
though his interest in the field stemmed from 
his experience as a runner who would often 
experience the “runner’s high”.
Currently, Banks is researching whether the 
use of an NMDA receptor antagonist called 
memantine would create an opioid sparing 
effect. The goal is to increase the therapeutic 
effect of an opioid, requiring a user to take less 
of the drug for pain management. An NMDA 
antagonist inhibits the action of the brain’s 
N-Methyl-D-aspartate receptor.
The use of animals in research can be 
controversial. The MCV campus houses a lab 
of rhesus monkeys, which are involved in much 
of Banks’ research. The Institutional Animal 
Care and Use Committee at VCU, as well as 
the federal agency providing a research grant, 
must review any proposals for use of laboratory 
animals to ensure the use is justified and 
the health and welfare of the animals will be 
protected. When not being studied, the monkeys 
live in a vivarium on campus.
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Monkeys are a good 
model for understanding 
why humans ‘go along 
this path of misallocating 
their behavior to abused 
drugs,’ Banks says.
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Research on animals can yield tremendous 
benefits. While primates make up only a half 
percent of all laboratory animals used, they have 
been crucial in many medical advances such as 
developing the polio vaccine, understanding the 
AIDS virus and searching for a vaccine for the 
Zika virus.
Humans share 90 percent of their genes with 
monkeys. Monkeys are a good model for 
understanding why humans “go along this path 
of misallocating their behavior to abused drugs,” 
Banks said.
Such research can help clinicians treat people 
with addictions and “get them to reallocate their 
behavior back to socially adaptive non-drug 
reinforcers,” he said.
While multiple pharmacotherapies exist for 
treating opiate addiction (such as methadone), 
the U.S. Food and Drug Administration has 
not approved treatments for cocaine and 
methamphetamine addiction.
Banks’ research on the drug phendimetrazine 
suggests that it may be a viable treatment for 
cocaine addiction. It “decreases cocaine vs. 
food choice under several different experimental 
conditions,” which means monkeys are more 
likely to choose food over cocaine after being 
administered the drug.
The compound acts as a dopamine transporter 
inhibitor like cocaine. Because it is a “prodrug,” 
the body metabolizes it into a pharmacologically 
active compound called phenmetrazine that 
acts as a dopamine transporter substrate (or 
releaser). This combination may represent an 
“innovative treatment strategy for cocaine use 
disorders,” Banks said.
He has discovered that although cocaine 
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Banks’ research on the 
drug phendimetrazine 
suggests that it may be 
a viable treatment for 
cocaine addiction.
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and methamphetamine share similar 
properties, the two drugs will require different 
pharmacotherapies to treat their abuse. To 
Banks, these discoveries are exciting as they 
represent exactly what “preclinical researchers 
hope to do – that is, impact human health in a 
positive manner.” •
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